Oxford Nanopore Technologies was founded in 2005 as a spin-out from the University of Oxford, built on nanopore sensing research developed by Professor Hagan Bayley and colleagues. The founding premise was that biological nanopores could be used to sequence DNA and RNA in real time, without the need for amplification or chemical labelling. That idea placed the company on a different technical trajectory from incumbent sequencing platforms from the outset.
The company's most significant inflection point came with the commercial launch of the MinION in 2014, a sequencer small enough to fit in a pocket and connect via USB. That form factor was not a gimmick; it enabled sequencing in field hospitals, remote agricultural settings, and outbreak response scenarios where laboratory infrastructure was absent. The platform gained notable attention during Ebola and Zika outbreak monitoring, and later during Covid-19 genomic surveillance efforts globally.
Oxford Nanopore listed on the London Stock Exchange in September 2021, raising approximately £350 million in one of the more prominent UK deep tech IPOs of that period. The listing gave the company a public profile and balance sheet to accelerate platform development and expand its product range beyond the MinION into higher-throughput instruments.
For operators and investors watching the life sciences tools sector, Oxford Nanopore represents a meaningful test case in two respects. First, it demonstrates whether a UK deep tech company can build durable commercial infrastructure around a genuinely novel scientific platform, rather than licensing the IP and stepping back. Second, its long-read sequencing approach sits in direct competition with established players, making its commercial progress a useful indicator of how quickly the sequencing market is willing to move away from short-read dominance. The company's trajectory matters beyond its own financials.